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Abstract
We developed a competition-based screening strategy to identify compounds that invert the 
selective advantage of antibiotic resistance. Using our assay, we screened over 19,000 compounds 
for the ability to select against the TetA tetracycline resistance efflux pump in E. coli and 
identified two hits: β-thujaplicin and disulfiram. Treating a tetracycline resistant population with 
β-thujaplicin selects for loss of the resistance gene, enabling an effective second-phase treatment 
with doxycycline.
The use of antibiotics promotes the emergence and spread of resistant strains, raising public 
health concerns1. Since the cost of resistance is typically small2,3, resistance alleles often 
remain in the population after fixation, even in the absence of antibiotics2. Inverting the 
evolutionary advantage of resistant bacteria and driving them back to drug susceptibility 
therefore requires treatments that impose substantial fitness costs to resistance alleles4–7.
Collateral sensitivity can be used to select against resistant strains in favor of drug 
susceptibility8. Collateral sensitivity occurs when an allele that confers resistance to one 
drug simultaneously increases sensitivity to another drug9. In such cases, bacteria that have 
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evolved resistance to drug A, can be penalized by their increased sensitivity to drug B. 
Treating with drug B can then drive the population back to drug A susceptibility8. In 
studying collateral sensitivity, many drugs have been found that select against de novo 
resistance mutations8–15. However, only a few drugs are known to select against specialized 
resistance genes and cassettes16–18, which encode major modes of clinical resistance such as 
efflux pumps, drug degrading enzymes, or modified targets19, and systematic screens for 
such selection-inverting compounds have been limited20.
Focusing on tetracycline resistance, we designed a high-throughput screen to identify 
selection-inverting compounds: small molecules that confer a disadvantage to a resistant 
strain compared to its susceptible parent. Tetracycline is a broad spectrum antibiotic whose 
use has dwindled, in part, due to widespread resistance21. The TetA efflux pump, often 
carried by transposons, is one of the most prevalent tetracycline resistance mechanisms21. In 
our assay, equally-fit tetracycline susceptible (TetS) and resistant (TetR, containing TetA) 
strains are differentially labeled with fluorescent proteins and competed on diffusion-
generated gradients of test compounds20 (Fig. 1a). This competition may be altered by a 
compound that preferentially inhibits one of the strains (Fig. 1b). As control compounds, we 
used doxycycline, a tetracycline analog that selects for tetracycline resistance (Fig. 1c); 
fusaric acid, a known molecule that selects against the TetA efflux pump but is of limited 
utility due to toxicity16,22 (Fig. 1d); ciprofloxacin, an antibiotic eliciting no or very mild 
selection for tetracycline resistance (Supplementary Results, Supplementary Fig. 1a); and a 
DMSO vehicle control (Supplementary Fig. 1b, 2). The media was supplemented with 
anhydrous tetracycline (ATC) at concentrations that induce expression of TetA but have no 
detectable effects on growth. We developed custom 48-well plates and an imaging platform 
for high throughput automation of the assay (Supplementary Fig. 1b, 3, Online Methods).
Screening 19,769 compounds, we identified two compounds that can select against the 
tetracycline resistance efflux pump. The primary screen identified 38 hits from three 
libraries: 30 known bioactives (0.34% of 8,752 screened), 8 natural product extracts (0.12% 
of 6,441), and 0 commercial library compounds (of 4,576, Supplementary Table 1). We 
verified positive hits by retesting them in our assay, in duplicate with a dye swap to control 
for autofluorescence. Of our 38 initial hits, two hits from the bioactives collection retested 
positive in both replicates: disulfiram and β-thujaplicin (also known as hinokitiol, Fig. 1d, 
Supplementary Fig. 4). Disulfiram is an FDA-approved drug (Antabuse) for treating 
alcoholism and acts synergistically with tetracycline in susceptible strains23. β-thujaplicin 
has widespread antifungal and antibacterial activity24. While these compounds were known 
to have antibacterial activity24,25, their ability to select against tetracycline resistance is a 
newly discovered property.
We evaluated the potency and selectivity of these compounds by testing them on the 
resistant and susceptible strains, separately and in competition. Measuring the dose-
responses of disulfiram, β-thujaplicin, and the fusaric acid control alone in liquid media 
further confirmed their differential ability to inhibit TetR compared to TetS (Supplementary 
Fig. 5; IC50 of TetR, TetS; disulfiram: 91 ± 3 μM, 133 ± 4 μM, p < 10−5; β-thujaplicin: 30 
± 1 μM, 39 ± 4 μM, p < 10−3; fusaric acid 106 ± 6 μM, 133 ± 14 μM, p = 10−3; mean ± s. d., 
N = 6, student’s t-test). We define potency as the IC50 against the sensitive strain. To 
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determine selectivity, we performed a competition assay in liquid media, mixing 
fluorescently labeled TetS and TetR strains 1:1, growing them in a linear dilution series of 
each compound for 24 h, and using flow cytometry to measure their final ratio (NS/NR, 
Supplementary Fig. 6a). Disulfiram and β-thujaplicin, as well as the fusaric acid control, 
gave a competitive advantage to the TetS over the TetR strain (Fig. 2a–b, Supplementary Fig. 
6b–e). For each compound, we then defined selectivity as the average selection (average of 
log10(NS/NR) over the range where at least one of the strains can grow, Fig. 6c–e). Its better 
potency, superior selectivity, and availability of chemical analogs led us to focus on β-
thujaplicin. A kill curve assay applying β-thujaplicin to co-cultures of fluorescently-labeled 
TetS and TetR strains showed specific killing of the TetR over the TetS strain (>3-fold 
difference in the bactericidal concentration; Supplementary Fig. 7).
To understand which chemical moieties of β-thujaplicin are critical for its antibacterial and 
selection properties, we measured the potency and selectivity of various β-thujaplicin 
analogs (Fig. 2a–b, Supplementary Fig. 5–6, 8–9, Supplementary Tables 2,3). β-thujaplicin 
far exceeded its analogs in both potency and selectivity (Fig. 2b). The regioisomer, α-
thujaplicin, had the same potency, but showed no selection between the TetS and TetR strains 
(Fig. 2b, compound 1; Supplementary Fig. 5d, 6f, Supplementary Table 2). From this 
structure-activity relationship, we infer that the hydroxyl group is required for potency, 
while the presence and position of the isopropyl group affects the degree of selection (Fig. 
2b).
While the hit compounds we identified preferentially inhibit the TetR strain, it remained 
unclear whether this cost of resistance was sufficient to evolve a resistant population back to 
tetracycline susceptibility. To answer this question, we propagated 8 replicate populations of 
the TetR strain in β-thujaplicin gradients for 7 days (each day propagating the population 
from the highest drug concentration that shows growth). In all 8 populations, the frequency 
of tetracycline resistant cells rapidly decreased, quickly falling below detection levels (10−6, 
Fig. 2c, Supplementary Fig. 10). To see if these populations, now tetracycline sensitive, 
would become tetracycline resistant upon treatment with doxycycline, we next passaged 
them in doxycycline gradients for 3 days. Only one of the eight populations regained 
tetracycline resistance. All other cultures permanently lost tetracycline resistance upon β-
thujaplicin treatment through deletion of tetA (Supplementary Fig. 11; Sanger sequencing 
revealed no mutations in marR), enabling effective doxycyline treatment. This suggests a 
two-phase treatment protocol in which a selection-inverting compound converts a resistant 
population to susceptibility and a traditional antibiotic clears any remaining bacteria.
To understand the frequency of tetracycline resistance loss and its underlying genotypic 
mechanisms, we performed a second selection experiment, isolating β-thujaplicin resistant 
(122 μM MIC) mutants derived from the TetR strain (91 μM MIC) and assayed their 
doxycycline phenotype. These mutants had the same β-thujaplicin MIC as the TetS strain 
(122 μM); no colonies appeared at or above this concentration. The vast majority of these 
isolates became doxycycline susceptible (TetS) upon β-thujaplicin selection (98/99, Fig. 2d). 
PCR amplification of the tetA gene showed that most had deleted tetA (77/99), while the 
rest had a 0.5–1 kb insertion in tetA (21/99, Fig. 2d, Supplementary Fig. 12). Whole genome 
sequencing of 6 ΔtetA isolates and 4 isolates with insertions in tetA confirmed these 
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changes. Two ΔtetA isolates also had single nucleotide polymorphisms (SNPs): one in cydD 
and one upstream of tyrP, but neither of these isolates displayed higher levels of β-
thujaplicin resistance (Supplementary Table 4). The one isolate that became β-thujaplicin 
resistant without losing tetA had a frameshift mutation in marR, the repressor of the multiple 
antibiotic resistance operon26 (Supplementary Table 4), suggesting a possible rare 
mechanism to evolve β-thujaplicin resistance without losing the tetracycline efflux pump. 
While this mutant had the same β-thujaplicin MIC as other β-thujaplicin resistant mutants, it 
also had a somewhat higher doxycycline MIC (234 μM) compared to the TetR strain (156 
μM MIC), highlighting the threat of potential cross-resistance. However, the marR mutant 
occurred at much lower frequencies (10−6) compared to deletions or insertions of tetA 
(10−4), consistent with previous studies on SNP-based resistance versus transposon loss18. 
Together, these data show that the vast majority of β-thujaplicin resistance appears through 
null insertions in or deletions of the tetA gene, while only rare cases evolve resistance to β-
thujaplicin through more general resistance pathways, without loss of tetracycline resistance. 
Similar results appear for disulfiram selection (78/81 lost tetracycline resistance: 75 ΔtetA, 1 
frameshift deletion in tetA, 1 insertion in tetA, and 1 insertion in tetR, Fig. 2d, 
Supplementary Fig. 13, 14).
Compounds that select against resistance genes can be systematically identified through 
competition-based screening and can be used in a two-phase treatment regimen against 
resistant infections. In this strategy, a first-phase treatment with a selection-inverting 
compound turns the resistant population sensitive, allowing an effective second-phase 
treatment with the classical antibiotic. The efficacy of this approach is enhanced by the 
presence of many antibiotic resistance genes on mobile elements21,26,27, which can be 
spontaneously lost at high frequency16,27. This strategy can be adapted to other organisms 
and resistance mechanisms for counter-selection in synthetic biology, microbial evolution, 
agriculture, and possibly therapeutics. However, bacterial populations can escape this 
treatment regimen through cross resistance mutations (such as the marR mutant) or 
mutations that provide resistance to the selection-inverting compound without losing 
antibiotic resistance. Resistance to the antibiotic in the second phase could further arise due 
to incomplete fixation of the antibiotic sensitive mutations during the first phase or due to 
reversal of these mutations in the second phase of treatment. The clinical application of this 
strategy may further be prohibited by its extended treatment times. Despite these difficulties, 
we hope these findings will inspire future therapeutic paradigms that can reverse the 
evolution of resistance4. Two-phase treatments beginning with selection-inverting 
compounds that counteract the evolutionary advantage of resistance could add valuable tools 
to our antimicrobial arsenal.
Online Methods
Strains and Media
All experiments were conducted in low salt LB broth (RPI, catalog #L24065), supplemented 
with bactoagar (BD Falcon) when noted. Drug solutions were made from powder stocks 
(anhydrotetracycline hydrochloride (ATC), catalogue no. 37919 (Sigma, analytical 
standard); doxycycline hyclate, catalogue no. D9891 (Sigma, ≥ 98.0%); ciprofloxacin, 
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catalogue no. 17850 (Fluka, ≥ 98.0%); fusaric acid, catalogue no. AC19896 (Fisher, 99%); 
β-thujaplicin, catalogue no. 469521 (Sigma, 99%); disulfiram, catalogue no. 86720 (Sigma, 
≥ 97.0%); α-thujaplicin (Fig. 2b, compound 1), catalogue no. 088-08701, (Wako, ≥ 98.0%); 
tropolone (compound 2), catalogue no. T89702 (Sigma, 98%); 2-Chloro-2,4,6-
cycloheptatrien-1-one (compound 3, chlorotropone), catalogue no. 669571, (Sigma, ≥ 
98.0%); 2-Methoxy-2,4,6-cycloheptatrien-1-one (compound 4, methoxytropone), catalogue 
no. 137-15711 (Wako, ≥ 98.0%); tropone (compound 5), catalogue no. 252832 (Sigma, 
97%) and filter-sterilized. All drug stocks were dissolved in DMSO at 15 mg/mL, except 
anhydrotetracycline hydrochloride, which was dissolved in EtOH at 1 mg/mL.
Strain construction and designations are in Supplementary Table 5. Plasmids expressing 
YFP or CFP under the PR promoter28 were constructed from the pZ vector system29. Assay 
strains were grown from single colonies to saturation in low salt LB. Cell concentrations 
were measured by OD600 and plate count. Aliquots were stored in 15% glycerol at −80°C. 
Fresh aliquots were used for each experiment.
Custom Assay Plate
We tailored a design for 48 well plates composed of 2 rows of 24 lanes20 to be compatible 
with high throughput screening robots by lowering the plate’s skirt and adding spacing bars 
so that air can escape as the agar cools while the plates are stacked (Supplementary Fig. 3).
Screen for Selection Inverters
Custom 48 well screening plates were filled with 352 μL/well low salt LB 1.5% bactoagar 
containing 80 ng/mL ATC using a Wellmate Stacker (ThermoScientific). Approximately 1 
μL/well test compounds were pinned onto the top of each lane using AFIX384FP6 (V&P 
Scientific) with FP6S pins (V&P Scientific) in rows A and I by the Seiko robot. 
Approximately 1 μL/well control compounds were pinned onto the top of each lane by hand 
using AFIX384FP (V&P Scientific) with FP6S pins (V&P Scientific) in appropriate wells. 
Each screening plate had at least one of each control: 15 mg/mL doxycycline, 15 mg/mL 
fusaric acid, 15 mg/mL ciprofloxacin, and DMSO vehicle control. Plates were stored at 4°C 
for 24 hours to allow the compounds to diffuse, creating concentration gradients down the 
length of the wells. Plates were then inoculated using a Wellmate Stacker with 112 μL/well 
frozen cell aliquots diluted 1:100 in low salt LB 0.75% bactoagar containing 80 ng/mL ATC. 
Each test compound is tested twice, with the fluorescent markers switched between the 
tetracycline susceptible and resistant strains to identify autofluorescent compounds. One 
replicate is inoculated with a 1:1 ratio of pY:t17pC and the other is inoculated with a 1:1 
ratio of pC:t17pY. Plates were incubated at 30°C and 70% humidity for 16–18 h. Finally, 
plates are automatically imaged in three channels, brightfield, CFP (436/20ex, 480/40em), 
and YFP (500/20ex, 530/20em) with a Canon T3i using a custom-built robotic fluorescent 
imaging ‘Macroscope’ device20.
As seen in Figure 1, the selection against resistance is concentration dependent—too much 
compound will kill both strains, while too little will allow both strains to grow. When 
screening for novel compounds that select against resistance, the concentration range in 
which they select is unknown. Employing diffusion gradients on agar allows rapid 
Stone et al. Page 5
Nat Chem Biol. Author manuscript; available in PMC 2017 March 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
assessment of a continuous range of concentrations using small amounts of library 
compounds. Allowing the compounds to diffuse for 24 h permits the compound gradient to 
somewhat stabilize before adding bacteria (the diffusion rate decreases with time as the 
compounds equilibrate), thus somewhat decoupling compound diffusion and bacterial 
growth. Because, the diffusion constants of most library compounds are unknown, their 
active range of concentration must be determined in follow-up studies using a defined 
dilution series of drug.
Screen Analysis
The images were processed using a custom MATLAB script. The blue channel from the CFP 
image and the green channel from the YFP image are reduced to grayscale images. A 
shading correction is employed to address nonuniformity in the field of illumination. The 
images are further processed by subtracting the background (the median intensity of an area 
of no bacterial growth) and normalizing to an area of neutral selection (the median intensity 
of the DMSO controls). Next, an RGB overlay image is created with the susceptible strain 
image in the green channel and the resistant strain image in the red channel, regardless of the 
fluorescent proteins involved. Using this overlay, the pixel intensity data is isolated for each 
well and the median is taken across the width of the well for the red and green channels. 
Wells with no inhibition of either strain are filtered out using a minimum intensity threshold. 
The remaining wells are scored by subtracting the distance to the half-max growth of the 
resistant strain from the distance to the half-max growth of the susceptible strain down the 
length of the well (Δd). Overlay images were evaluated by eye in addition to the automated 
ranking of hits. Using the Δd metric, doxycycline (selection for resistance control) and 
fusaric acid (selection against resistance control) were identified in comparison to 
ciprofloxacin (inhibition with no selection control) and DMSO (no inhibition or selection 
control). The Z′ factor was 0.62 for the fusaric acid control and 0.87 for the doxycycline 
control.
Growth Curve Assay
Clear, flat-bottomed 96-well plates (Corning 3370) were filled with 150 μL/well low salt LB 
with 80 ng/mL ATC containing linear dilution series of DMSO and ~104 cells/well WT 
(TetS) or ~104 cells/well t17 (TetR) cells. Experiments are run in parallel with 4 replicates. 
The plates are incubated for 24 h at 30°C, 70% humidity with shaking. Growth was 
measured every 12 minutes by optical density at 600 nm (OD600) on an Envision plate 
reader (Perkin Elmer).
Petri Competition Assay
Petri dishes (100mm × 15 mm, BD Falcon) were filled with 20 mL low salt LB 1.5% 
bactoagar containing 80 ng/mL ATC. Drug stocks were pipetted onto the plate (3μL of 15 
mg/mL fusaric acid, 1 μL of 15 mg/mL β-thujaplicin, and 6 μL of 15 mg/mL disulfiram 
dissolved in DMSO) and allowed to diffuse at 4°C for 24 h. The plates were then inoculated 
with 100 μL of a 1:100 dilution of frozen cell aliquots in phosphate buffered saline (PBS). 
One replicate is inoculated with a 1:1 ratio of pY:t17pC and the other is inoculated with a 
1:1 ratio of pC:t17pY. Plates were incubated at 30°C and 70% humidity for 16–18 h, then 
imaged in brightfield, CFP, and YFP with the ‘Macroscope’ device20.
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Kill Curve Assay
Frozen aliquots of fluorescently-labeled TetR and TetS cells (pY, t17pC, pC, and t17pY) 
were diluted 1:104 in 20 mL LB with 80 ng/mL ATC and grown to ~0.05 OD600 at 30°C, 
250 rpm. TetS and TetR were then mixed 1:1 according to OD600 measurement (two dye 
swaps: pY:t17pC and pC:t17pY). A 10-fold dilution series of these initial cell mixtures (t = 
0) was plated onto LB-agar petri dishes to count initial CFU. These two co-cultures were 
then aliquoted 1mL/well into a row of a 96 deep well plate and β-thujaplicin was added to 
each well at a series of concentrations (indicted in Supplementary Fig. 6). To measure 
surviving cells as a function of time, 50 μL aliquots were taken at 10, 20, 30, 45, 60, 90 and 
180 min timepoints and an 8-step, 10-fold dilution series of each well at each timepoint was 
drop-plated (7 μL/drop) onto an omnitray filled with 30 mL LB-agar to count CFU (total of 
2 dye swaps × 12 drug concentrations × 7 timepoints × 8 dilutions = 1344 drops plated for 
CFU). Plates were incubated at 30°C for ~12 h. Colonies were imaged in brightfield, CFP, 
and YFP with the ‘Macroscope’ device20 and counted using MATLAB scripts and visual 
inspection. CFU/mL of each strain was calculated based on the most dilute drop with ≥ 10 
colonies of that strain at each drug concentration, at each timepoint.
IC50 Measurements
Clear, flat-bottomed 96-well plates (Corning 3370) were filled with 150 μL/well low salt LB 
containing linear dilution series of drug, ~104 cells/well WT (TetS), and ~104 cells/well t17 
(TetR) cells. Experiments are run in parallel: at least 6 replicates with and 6 replicates 
without 80 ng/mL ATC to show that fitness differences are dependent on the expression of 
the TetA pump. The plates are sealed with Aeraseal (EXCEL) to limit evaporation and 
incubated for 24 h at 30°C with shaking at 900 rpm on Titramax 1000 (Heidolph). Growth 
was measured by optical density at 600 nm (OD600) on a Victor3 plate reader (Perkin 
Elmer). The dose responses are fit to a 4 parameter logistic function c + (d − c)/(1 + (x/a)b) 
where a is the IC50, b is the slope parameter, c is the minimum response level, and d is the 
maximum response level. Normality and homogeneity of variance confirmed by Shapiro-
Wilk test and Levene’s test, respectively. Significance determined by student’s t-test.
Flow Cytometry Competition Assay
Clear, flat-bottomed 96-well plates (Corning 3370) were filled with 150 μL/well low salt LB 
containing linear dilution series of drug and ~104 cells/well fluorescently-labeled TetS and 
~104 cells/well fluorescently-labeled TetR cells. Experiments are run in parallel with a dye 
swap (pY & t17pC in one set of plates and pC & t17pY in another set) to show that fitness 
differences do not depend on the fluorescent proteins and with and without 80 ng/mL ATC 
to show that fitness differences are dependent on the expression of the TetA pump. The 
plates are sealed with Aeraseal (EXCEL) to limit evaporation and incubated for 24 h at 30°C 
with shaking at 900 rpm on Titramax 1000 (Heidolph). The saturated cultures were diluted 
1:100 by pinning ~1.5 μL/well culture into 150 μL PBS with VP407 (V&P Scientific). Cells 
were counted by flow cytometry (Becton Dickinson LSRII; CFP excited at 405nm, emission 
detected through 505LP and 525/550nm filters; YFP excited at 488nm, emission also 
detected through 505LP and 525/550nm filters). The ratio of TetS to TetR cells (NS/NR) was 
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normalized to the mean NS/NR of eight no drug wells on each plate. Results in Figure 3 are 
the average of 5 replicates performed with pC and t17pY cells and 80 ng/mL ATC.
Passaging Experiment
Clear, flat-bottomed 96-well plates (Corning 3370) were filled to a final volume of 150 μL/
well low salt LB with 80 ng/mL ATC. Each column contained a linear dilution series of β-
thujaplicin or doxycycline. Each plate included one column inoculated with WT ancestral 
control, one column inoculated with t17 ancestral control, and one column with no bacteria 
to control for contamination. Nine columns contained replicate populations of t17 passaged 
each day into fresh β-thujaplicin for 7 days, then in doxycycline for 3 days (β-thujaplicin 
evolved strains). In addition, 3 replicate populations of t17 were passaged in a fixed DMSO 
concentration equivalent to the highest DMSO concentration used in the β-thujaplicin 
dilution series (DMSO evolved strains). Plates were inoculated with ~104 cells/well. The 
plates are sealed with Aeraseal (EXCEL) to limit evaporation and incubated for 22 h at 30°C 
with shaking at 900 rpm on Titramax 1000 (Heidolph). Growth was measured by optical 
density at 600 nm (OD600) on a Victor3 plate reader (Perkin Elmer). For each evolved 
strain, the well containing the highest drug concentration with OD600 ≥ 0.4 was diluted and 
propagated daily into fresh drug plates with ~104 cells/well. The remainder of the well was 
stored in 15% glycerol at −80°C. The wells with WT and t17 ancestral controls and no drug 
were also stored in 15% glycerol at −80°C to serve as controls for later follow up. One of the 
nine β-thujaplicin lineages was contaminated in storage and is excluded from Fig. 4.
The TetR frequency was measured by creating a 10-fold dilution series of stored evolved 
strains and ancestral controls in PBS. Using VP407, ~1.5 μL/well of these dilution series and 
the storage wells were pinned onto one non-treated omnitray (Thermo Scientific) containing 
30 mL low salt LB 1.5% bactoagar and one non-treated omnitray containing 30 mL low salt 
LB 1.5% bactoagar and 20 μg/mL doxycycline. The plates were incubated at 30°C for 22 h 
then imaged. Growth was then measured by eye with positive growth meaning that at least 
one colony grew from the spot. The cfu/mL of the dilution series was calibrated by plating 
50 μL of select wells onto petri dishes containing 20 mL low salt LB 1.5% bactoagar. The 
data from pinning is precise to one order of magnitude. The accuracy of this method was 
confirmed by plating 50 μL/well of a subset of samples onto petri dishes containing 20 mL 
low salt LB 1.5% bactoagar and onto petri dishes containing 20 mL low salt LB 1.5% 
bactoagar and 20 μg/mL doxycycline.
Resistant Mutant Selection
The t17 strain was streaked on a low salt LB 1.5% bactoagar petri dish and grown overnight 
at 30°C. A single colony was picked and grown overnight in low salt LB to saturation (~2 × 
109 cells/mL). This culture was spun down at 3000 rpm & 4°C and the supernatants 
decanted. The culture was re-suspended in PBS, spun down again, the supernatants 
decanted, and re-suspended in PBS to a density of ~107 cells/mL. Petri dishes containing 20 
mL low salt LB 1.5% bactoagar, 80 ng/mL ATC, and either 40 μg/mL disulfiram or 15 
μg/mL β-thujaplicin were inoculated with ~106 t17 cells/plate. The plates were incubated at 
30°C, 70% humidity, protected from light. Disulfiram plates were incubated for 3 days and 
β-thujaplicin plates were incubated for 6 days.
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One hundred colonies from the β-thujaplicin and disulfiram selection plates were streaked 
onto LB agar petri dishes and incubated overnight at 30°C. One colony from each streak was 
transferred to deep 96 well plates containing 1 mL/well low salt LB. A subset of the plate 
was inoculated with WT or t17 ancestral controls or left empty to control for cross 
contamination. The plates were sealed with Aeraseals and incubated at 30°C with 600 rpm 
shaking on a Titramax. Using VP407, ~1.5 μL/well was transferred from these overnight 
plates onto omnitrays containing low salt LB 1.5% bactoagar, 80 ng/mL ATC, and drug (5, 
10, 15, 20, 25, 30 μg/mL β-thujaplicin; 10, 20, 30, 40, 50, 60 μg/mL disulfiram; 0, 0.1, 1, 5, 
10, 20, 40, 60, 80, 100 μg/mL doxycycline). Omnitrays were incubated at 30°C for 20 h. 
Plates were imaged and growth was recorded (single colonies or films were recorded as no 
growth). The minimum inhibitory concentration (MIC) was determined as the lowest 
concentration at which the strains did not grow.
Detection of tetA, tetR, and marR by PCR
The tetA, tetR, and marR genes were amplified with the primers (Supplementary Table 6) in 
25 μL reactions using 0.2 μL OneTaq (New England Biolabs) according to the supplier’s 
protocol. Reactions were cycled 30 times, with an annealing temperature of 57°C for tetA 
and marR and 59°C for tetR. PCR product size was determined by gel electrophoresis on a 
1% agarose gel (Supplementary Fig. 9–11). The bands were compared to a 1 kb DNA ladder 
(New Englad Biolabs) and their size was determined within 0.5 kb. The expected band size 
is 1086 bp for tetA, 1045 bp for tetR, and 611 bp for marR if the genes are present and 
uninterrupted. The marR PCR product was sent for Sanger sequencing (Genewiz, Boston, 
MA).
One mutant, disulfiram resistant colony 19 (DsfRP1C10), was tetracycline susceptible 
despite having the expected length PCR products for both tetA and tetR. The tetA and tetR 
PCR products of this colony and the TetR t17 control were purified (QIAGEN) and Sanger 
sequenced at Genewiz, Boston, MA. Sanger sequencing revealed an 11 bp (frameshift) 
deletion in tetA in disulfiram resistant colony 19 (DsfRP1C10).
Genomic sequencing of β-thujaplicin resistant colonies
Genomic DNA was extracted from 1 mL cultures of eleven colonies and the ancestral t17 
control using illustra bacteria GenomicPrep Mini Spin Kit (GE Healthcare) following the 
supplier’s protocol, except eluting with water instead of elution buffer. Purified DNA was 
quantified using the Quant-iT™ High-Sensitivity DNA Assay Kit (Life Technologies). 
Sequencing libraries were prepared using the Nextera XT DNA Sample Preparation Kit 
(Illumina), using a previously described protocol30. Samples were sequenced using 100bp 
paired-end reads on the HiSeq platform at Axeq Technologies, Seoul, South Korea. Adaptors 
were removed using cutadapt31, reads were trimmed using Sickle, and trimmed reads were 
aligned to both the E. coli MC4100 reference genome and Tn10 (Genbank accession 
numbers NC_012759.1 and AF162223.1, respectively) using Bowtie232. Over 99.7% of 
reads aligned to the reference genome, and average coverage across a sample ranged 
between 33× and 134× (median 65x). SNPs were identified using SAMtools33 and 
consensus quality (FQ score) cutoff of less than −55 for inclusion. At each variant position 
that met this cutoff in at least one strain, a best call was made based on the aligned reads for 
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each strain, and positions where all strains supported a variant were discarded. Small 
insertions and deletions (indels) were called using Dindel34. Candidate indels found in one 
strain were explicitly tested for in all strains; indels with at least 70% of reads in the region 
supporting the indel and at positions with an average of at least 10× coverage across isolates 
were accepted. Tn10 deletions were identified by the absence of reads aligning to the coding 
section of AF162223.1. Insertion elements were identified using RetroSeq35 (FL score of 6 
or 8).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. A high throughput diffusion-based screen identifies compounds that select against 
tetracycline resistance
(a) Tetracycline susceptible and resistant strains (TetS: CFP, shown in green; TetR: TetA, 
YFP, shown in red; a dye swap control is also performed) are mixed 1:1 and plated on agar 
lanes with diffusion gradients of locally spotted drugs. (b) Fluorescent imaging reveals 
regions of selection along the drug gradient. Areas where both strains can grow maintain a 
1:1 ratio and appear yellow; areas where neither strain can grow appear dark, while areas 
selecting for resistance or susceptibility appear red or green, respectively. (c–d) Automated 
image analysis identifies the distance from the drug spot where each strain can grow 
(defined by half-maximal fluorescence). The difference between these points (Δd) is used to 
score hits: Δd < 0 indicates selection for resistance (c, doxycycline control) and Δd > 0 
indicates selection against resistance (d, fusaric acid control). (d) Hit compounds disulfiram 
and β-thujaplicin select for tetracycline susceptibility.
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Figure 2. β-thujaplicin and disulfiram select for loss of tetracycline resistance
(a) β-thujaplicin and its analogs. (b) The advantage of the TetS over the TetR strain at each 
drug concentration is measured by the ratio NS/NR, determined by flow cytometry, and 
normalized to the ratio of NS/NR with no drug. The selectivity of the drug is represented by 
the average selection (normalized log10(NS/NR)) across the concentrations where at least 
one of the strains can grow. Examining all compounds for selectivity (mean ± s.d., n = 5) 
and potency (TetS IC50, mean ± s.d., n = 6) shows that β-thujaplicin exerts the greatest 
selection for TetS among its analogs and has better potency compared to fusaric acid. (c) 
When evolved in β-thujaplicin (days 1–7), eight parallel populations of the TetR strain lose 
their tetracycline resistance phenotype, with the frequency of resistant cells rapidly falling 
below the detection limit (10−6). In a second selection phase (days 8–10), the lineages were 
evolved in doxycycline, yet the majority did not regain tetracycline resistance (7/8). In 
contrast, all (3/3) lineages that were evolved for 7 days in DMSO (blue) remained 
tetracycline resistant. Points are offset slightly to resolve overlaps. (d) The vast majority of 
β-thujaplicin and disulfiram resistant mutants selected from the TetR strain lost phenotypic 
resistance to tetracycline (TetS, green and light green). Most tetracycline susceptible (TetS) 
mutants completely lost tetA (green); others (light green) had insertions within tetA (21/99 
β-thujaplicin mutants, 1 disulfiram mutant) or tetR (1 disulfiram mutant) or had an 11bp 
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deletion within tetA (1 disulfiram mutant). Only 1 β-thujaplicin resistant mutant and 3 
disulfiram resistant mutants remained tetracycline resistant (TetR, red), with an intact tetA 
gene.
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